Partnering opportunity

Stem cell extracellular vesicles therapy to turn off ischemic inflammation


A leading Italian public medical research centre committed to healthcare and translational medicine has developed an innovative therapeutic solution based on extracellular vesicles (EV) for treatment of secondary damage effects on ischemic tissues. The medical research centre is looking for industrial partners interested in a licensing agreement or a technical cooperation agreement.

Partner sought

Type and tasks of partner sought: industrial partner in the healthcare sector willing to commercialize the technology by specific license agreements or to collaborate with the medical centre to further the development of the technology by a technical agreement.


Disorders characterized by ischemia/reperfusion, such as myocardial infarction, stroke, and peripheral vascular disease, continue to be among the most frequent causes of debilitating disease and death. Currently, no broad and effective therapeutic approaches are available most of all due to the very short timeframe (3-6 hours) from stroke symptom onset in which a patient is eligible to receive the tissue plasminogen activator, the only thrombolytic agent able to reduce the secondary effects of ischemia. The Italian public medical research centre has selected and isolated human mesenchymal stem cells, renowned for their beneficial effects in pathological contexts of acute damage. After a reprogramming process (repCBMSC), the researchers identified a specific set of microRNA (miRNA) able to modulate inflammation in both parental Cord Blood Mesenchymal Stromal Cells - Extracellular vesicles (CBMSC-EV) and Reprogrammed Cord Blood Mesenchymal Stromal Cells - Extracellular vesicles (repCBMSC-EV). This set of miRNA was successfully challenged in a model of brain ischemia, where necrosis was significantly reduced. The Italian medical research centre is looking for industrial partners interested in a licensing agreement of the technology or in technical agreement for co-development.

Advantages and innovations

The most innovative aspects of this technology are: - Protective/reparative effect correlated with significant tissue level reduction of apoptotic/inflammatory Tumor necrosis factor (TNFα, 4-fold) and Interferon gamma (INFγ, 3-fold). - Significant necrosis damage reduction.

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted,Exclusive Rights

Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company